233 related articles for article (PubMed ID: 19154430)
1. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation.
Liu JY; Tsai HJ; Hwang SH; Jones PD; Morisseau C; Hammock BD
Br J Pharmacol; 2009 Jan; 156(2):284-96. PubMed ID: 19154430
[TBL] [Abstract][Full Text] [Related]
2. Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models.
Liu JY; Lin YP; Qiu H; Morisseau C; Rose TE; Hwang SH; Chiamvimonvat N; Hammock BD
Eur J Pharm Sci; 2013 Mar; 48(4-5):619-27. PubMed ID: 23291046
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.
Tsai HJ; Hwang SH; Morisseau C; Yang J; Jones PD; Kasagami T; Kim IH; Hammock BD
Eur J Pharm Sci; 2010 Jun; 40(3):222-38. PubMed ID: 20359531
[TBL] [Abstract][Full Text] [Related]
4. Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.
Savina Y; Duflot T; Bounoure F; Kotzki S; Thiebaut PA; Serreau PA; Skiba M; Picquenot JM; Cornic M; Morisseau C; Hammock B; Imbert L; Cracowski JL; Richard V; Roustit M; Bellien J
Diab Vasc Dis Res; 2019 Nov; 16(6):523-529. PubMed ID: 31267765
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.
Chaudhary KR; Abukhashim M; Hwang SH; Hammock BD; Seubert JM
J Cardiovasc Pharmacol; 2010 Jan; 55(1):67-73. PubMed ID: 19834332
[TBL] [Abstract][Full Text] [Related]
6. Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction.
Gui Y; Li D; Chen J; Wang Y; Hu J; Liao C; Deng L; Xiang Q; Yang T; Du X; Zhang S; Xu D
Lipids Health Dis; 2018 May; 17(1):129. PubMed ID: 29843720
[TBL] [Abstract][Full Text] [Related]
7. Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Hwang SH; Tsai HJ; Liu JY; Morisseau C; Hammock BD
J Med Chem; 2007 Aug; 50(16):3825-40. PubMed ID: 17616115
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors.
Schmelzer KR; Inceoglu B; Kubala L; Kim IH; Jinks SL; Eiserich JP; Hammock BD
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13646-51. PubMed ID: 16950874
[TBL] [Abstract][Full Text] [Related]
9. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
[TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
Roche C; Besnier M; Cassel R; Harouki N; Coquerel D; Guerrot D; Nicol L; Loizon E; Remy-Jouet I; Morisseau C; Mulder P; Ouvrard-Pascaud A; Madec AM; Richard V; Bellien J
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1020-9. PubMed ID: 25724490
[TBL] [Abstract][Full Text] [Related]
11. Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.
Shaik JS; Ahmad M; Li W; Rose ME; Foley LM; Hitchens TK; Graham SH; Hwang SH; Hammock BD; Poloyac SM
Am J Physiol Heart Circ Physiol; 2013 Dec; 305(11):H1605-13. PubMed ID: 24043255
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.
Ulu A; Appt S; Morisseau C; Hwang SH; Jones PD; Rose TE; Dong H; Lango J; Yang J; Tsai HJ; Miyabe C; Fortenbach C; Adams MR; Hammock BD
Br J Pharmacol; 2012 Mar; 165(5):1401-12. PubMed ID: 21880036
[TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes.
Liu Q; Zhao X; Peng R; Wang M; Zhao W; Gui YJ; Liao CX; Xu DY
Mol Biosyst; 2017 Feb; 13(3):556-564. PubMed ID: 28112313
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.
Liu JY; Yang J; Inceoglu B; Qiu H; Ulu A; Hwang SH; Chiamvimonvat N; Hammock BD
Biochem Pharmacol; 2010 Mar; 79(6):880-7. PubMed ID: 19896470
[TBL] [Abstract][Full Text] [Related]
15. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
Honetschlägerová Z; Husková Z; Vaňourková Z; Sporková A; Kramer HJ; Hwang SH; Tsai HJ; Hammock BD; Imig JD; Červenka L; Kopkan L
J Physiol; 2011 Jan; 589(Pt 1):207-19. PubMed ID: 21078594
[TBL] [Abstract][Full Text] [Related]
16. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.
Kim IH; Nishi K; Tsai HJ; Bradford T; Koda Y; Watanabe T; Morisseau C; Blanchfield J; Toth I; Hammock BD
Bioorg Med Chem; 2007 Jan; 15(1):312-23. PubMed ID: 17046265
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
18. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice.
Zhang W; Yang AL; Liao J; Li H; Dong H; Chung YT; Bai H; Matkowskyj KA; Hammock BD; Yang GY
Dig Dis Sci; 2012 Oct; 57(10):2580-91. PubMed ID: 22588244
[TBL] [Abstract][Full Text] [Related]
19. Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Zhang W; Koerner IP; Noppens R; Grafe M; Tsai HJ; Morisseau C; Luria A; Hammock BD; Falck JR; Alkayed NJ
J Cereb Blood Flow Metab; 2007 Dec; 27(12):1931-40. PubMed ID: 17440491
[TBL] [Abstract][Full Text] [Related]
20. Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
Roche C; Guerrot D; Harouki N; Duflot T; Besnier M; Rémy-Jouet I; Renet S; Dumesnil A; Lejeune A; Morisseau C; Richard V; Bellien J
Prostaglandins Other Lipid Mediat; 2015 Jul; 120():148-54. PubMed ID: 26022136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
